Overview of FDA's Expanded Access Program for Investigational Drugs

Expanded access, also called "compassionate use," provides a pathway for patients to gain access to investigational drugs, biologics, and medical devices used to diagnose, monitor, or treat patients with serious diseases or conditions for which there are no comparable or satisfactory therapy options available outside of clinical trials. The US Food and Drug Administration (FDA) facilitates the expanded access process; however, access to investigational treatments requires not only FDA's review and authorization but also the active involvement and cooperation of other parties, including drug companies and health care providers, in order to be successful.

Keywords: expanded access; investigational new drug; investigational therapies; single patient expanded access.

Conflict of interest statement

Declaration of Conflicting Interests No potential conflicts were declared.

Similar articles

Rossen BR. Rossen BR. Food Drug Law J. 2009;64(1):183-223. Food Drug Law J. 2009. PMID: 19998746

Scepura B, Chan M, Kim T, Boehmer J, Goldberg KB, Pazdur R. Scepura B, et al. Oncologist. 2021 Oct;26(10):e1880-e1882. doi: 10.1002/onco.13910. Epub 2021 Aug 11. Oncologist. 2021. PMID: 34288259 Free PMC article.

Jarow JP, Lemery S, Bugin K, Lowy N. Jarow JP, et al. Ther Innov Regul Sci. 2017 Mar 1;51(2):246-249. doi: 10.1177/2168479016679214. Ther Innov Regul Sci. 2017. PMID: 28553566 Free PMC article.

Speers MA. Speers MA. Pharmaceut Med. 2019 Apr;33(2):89-98. doi: 10.1007/s40290-019-00274-3. Pharmaceut Med. 2019. PMID: 31933253 Review.

McKee AE, Markon AO, Chan-Tack KM, Lurie P. McKee AE, et al. J Clin Pharmacol. 2017 Oct;57 Suppl 10:S136-S142. doi: 10.1002/jcph.960. J Clin Pharmacol. 2017. PMID: 28921646 Review.

Cited by

Michaeli DT, Michaeli T, Albers S, Boch T, Michaeli JC. Michaeli DT, et al. Eur J Health Econ. 2024 Aug;25(6):979-997. doi: 10.1007/s10198-023-01639-x. Epub 2023 Nov 14. Eur J Health Econ. 2024. PMID: 37962724 Free PMC article. Review.

Joly MM, Edwards TL, Jerome RN, Mainor A, Bernard GR, Pulley JM. Joly MM, et al. Front Med (Lausanne). 2023 Oct 9;10:1287449. doi: 10.3389/fmed.2023.1287449. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37877021 Free PMC article.

Vermeulen SF, Hordijk M, Visser RJ, Bunnik EM. Vermeulen SF, et al. J Law Med Ethics. 2023;51(1):172-180. doi: 10.1017/jme.2023.53. Epub 2023 May 25. J Law Med Ethics. 2023. PMID: 37226748 Free PMC article.

Fialho BC, Gauss L, Soares PF, Medeiros MZ, Lacerda DP. Fialho BC, et al. J Pharm Innov. 2023 Feb 13:1-49. doi: 10.1007/s12247-023-09708-7. Online ahead of print. J Pharm Innov. 2023. PMID: 36818394 Free PMC article.

Jaglan AB, Anand T, Verma R, Vashisth M, Virmani N, Bera BC, Vaid RK, Tripathi BN. Jaglan AB, et al. Front Microbiol. 2022 Nov 24;13:993990. doi: 10.3389/fmicb.2022.993990. eCollection 2022. Front Microbiol. 2022. PMID: 36504807 Free PMC article. Review.

References

    1. [Accessed July 26, 2016];21 CFR Parts 312, 314, 511, and 514: New Drug, Antibiotic, and Biologic Drug Product Regulations (IND Rewrite) http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/u. Published March 19, 1987. Updated August 5, 2010.
    1. [Accessed July 26, 2016];Federal Register. 2009 Aug Thursday 13;74(155) https://www.gpo.gov/fdsys/pkg/FR-2009-08-13/pdf/E9-19005.pdf.
    1. Investigational New Drug Application, Subpart I–Expanded Access to Investigational Drugs for Treatment Use. (Food and Drugs, 21 C.F.R. §312.300–312.320 (2009).
    1. Mackey TK, Schoenfeld VJ. Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Med. 2016;14:17. - PMC - PubMed
    1. Caplan A, Ray A. The ethical challenges of compassionate use. JAMA. 2016;315(10):979–980. - PubMed